Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. (Q36564872)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Lajos Pusztai

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

12 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

1951-1958

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer

28 December 2019

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-006-9075-5

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-006-9075-5

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

21 January 2018

1 reference

12 December 2020

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

1 reference

12 December 2020

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

1 reference

12 December 2020

Outcome signature genes in breast cancer: is there a unique set?

1 reference

12 December 2020

p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase

1 reference

12 December 2020

The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy

1 reference

12 December 2020

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

1 reference

12 December 2020

Reproducibility of gene expression signature-based predictions in replicate experiments

1 reference

12 December 2020

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

1 reference

12 December 2020

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

12 December 2020

Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

1 reference

12 December 2020

Cell-type-specific responses to chemotherapeutics in breast cancer

1 reference

12 December 2020

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

12 December 2020

Molecular portraits of human breast tumours

1 reference

12 December 2020

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

12 December 2020

HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.

1 reference

12 December 2020

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

12 December 2020

Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes

1 reference

12 December 2020

Prediction of cancer outcome with microarrays: a multiple random validation strategy

1 reference

12 December 2020

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

1 reference

12 December 2020

p53 and chemosensitivity.

1 reference

12 December 2020

The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study

1 reference

12 December 2020

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

12 December 2020

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer

1 reference

12 December 2020

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

1 reference

12 December 2020

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

12 December 2020

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

1 reference

12 December 2020

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

1 reference

12 December 2020

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.

1 reference

12 December 2020

HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses

1 reference

12 December 2020

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer

1 reference

12 December 2020

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

12 December 2020

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

1 reference

12 December 2020

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

1 reference

12 December 2020

The evolving role of capecitabine in breast cancer

1 reference

12 December 2020

Standardizing global gene expression analysis between laboratories and across platforms.

1 reference

12 December 2020

Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer

1 reference

12 December 2020

Gene expression predictors of breast cancer outcomes

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

12 December 2020

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil

1 reference

12 December 2020

Gene ontology: tool for the unification of biology

1 reference

12 December 2020

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

1 reference

12 December 2020

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

12 December 2020

Multiple-laboratory comparison of microarray platforms

1 reference

12 December 2020

10.1007/S11095-006-9075-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16906452%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference